I-ACT for Children to ramp up Covid-19 paediatric trials

The Institute for Advanced Clinical Trials for Children (I-ACT for Children) has launched Covid-19 Emergency Access Programme to speed up the development of pediatric Covid-19 trials.

Earlier last month, the Centers for Disease Control and Prevention reported that about 1.7% of Covid-19 infections had occurred in children who are aged 18 years and below. Credit: fernando zhiminaicela from Pixabay.

The Institute for Advanced Clinical Trials for Children (I-ACT for Children) has launched the Covid-19 Emergency Access Programme to speed up the development of pediatric Covid-19 trials.

This access programme allows companies to access the organisation’s trial-planning experts and pediatric trial network to accelerate the development of coronavirus treatments and vaccines.

The launch of I-ACT’s programme allows any company developing Covid-19 treatments/vaccines, including non-members, to access the organisation’s pediatric research network in order to conduct their pediatric clinical trials with respect to coronavirus.

Earlier last month, the Centers for Disease Control and Prevention (CDC) reported that roughly 1.7% of Covid-19 infections had occurred in children aged 18 and below.

I-ACT for Children chief medical officer Gary Noel said: “The immediate research focus has rightly been on the adults who make up the majority of severe Covid-19 cases, but we cannot neglect the needs of children who are becoming seriously ill with Covid-19.

“We must ensure that as treatments and vaccines are developed, children are included in clinical trials so that they can benefit from advances just as adults do.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Tick here to opt out of curated industry news, reports, and event updates from Clinical Trials Arena.

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to I-ACT, non-member companies will be able to work with I-ACT for Children to plan and execute Covid-19 clinical trials as part of the new emergency access programme.

Based in the US, I-ACT for Children is a non-profit organisation engaged in the advancement of paediatric clinical trials.

The company aims to provide unmet medical needs by supporting the development of novel medicines and devices for children.

It also seeks to optimise biomedical innovation using child-centered clinical trial networks by collaborating with like-minded institutions and other stakeholders.

The I-ACT for Children site network currently operates 62 US paediatric research sites.

In May last year, I-ACT for Children selected Advarra to provide central institutional review board (IRB) services to accelerate its paediatric clinical trials network.